BPC-157
Synthetic Pentadecapeptide - Synthetic pentadecapeptide studied for VEGF and growth-factor receptor signaling.
BPC-157 is a synthetic 15-residue peptide corresponding to a partial sequence identified in gastric juice. It is characterized in the preclinical literature for its interaction with the VEGF/VEGFR2 and nitric-oxide signaling axes, and for reported modulation of growth-hormone-receptor expression in cultured fibroblasts. Supplied as a characterized reference standard for in-vitro receptor and pathway work.
Interest in BPC-157 centers on VEGF/VEGFR2 and nitric-oxide pathway activity, where much of the literature comes from a single prolific group and is almost entirely rodent-based. In the laboratory it is handled as a stable lyophilized powder, reconstituted per the study protocol, and it is frequently paired with TB-500 in combination assay work.
BPC-157 specifications
- CAS number
- 137525-51-0
- Molecular formula
- C62H98N16O22
- Molecular weight
- 1419.53 g/mol
- Sequence
- Synthetic pentadecapeptide (15 amino acids)
- Residues
- 15 residues
- Presentation
- Lyophilized powder
- Documented purity
- 99.51% by HPLC
- Available sizes
- 10mg ($40), 20mg (out of stock)
- Archived COA lots
- 4
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- VEGF / VEGFR2 signaling - Studied for upregulation of vascular endothelial growth factor expression and downstream VEGFR2 pathway activity in cell and animal model systems.
- Growth-factor receptor expression - Reported to modulate growth-hormone-receptor expression in cultured tendon fibroblasts in preclinical assay systems.
- Nitric-oxide system - Described in the literature as interacting with the nitric-oxide synthase system across preclinical model systems.
Reported mechanisms in the literature
- VEGF / VEGFR2 signaling - Studied for upregulation of vascular endothelial growth factor expression and modulation of the nitric-oxide system in cell and animal model systems. (Sikirić et al.)
- Fibroblast receptor expression - Reported to raise growth-hormone-receptor expression in cultured tendon fibroblasts and to alter collagen-gene expression markers in preclinical assay systems. (Chang et al.)
- NOS system interaction - Described in the literature as interacting with the nitric-oxide synthase system across gastrointestinal and musculoskeletal model systems. (Sikirić et al.)
What BPC-157 is researched for
- Angiogenic signaling - Studied for vascular endothelial growth factor expression and downstream VEGFR2 pathway activity in cell and animal model systems. (Sikirić et al.)
- Receptor expression - Reported modulation of growth-hormone-receptor expression in cultured tendon fibroblasts. (Chang et al.)
- NOS system - Described as interacting with the nitric-oxide synthase system across preclinical model systems. (Sikirić et al.)
- Collagen gene expression - Investigated for effects on collagen-gene expression markers in cell-based assays. (Sikirić et al.)
BPC-157 certificates of analysis on file
Every lot below was tested by an independent laboratory and the full report is published as a PDF. Purity is shown exactly as the report states it. The same records are searchable in the COA library and can be checked on the lot verification page.
| Lot | Tested | Size | Laboratory | HPLC purity | Identity | Certificate |
|---|---|---|---|---|---|---|
| 2ES6TK | 15 Sep 2026 | 10mg | Freedom Diagnostics | 99.86% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2605270306 | 29 May 2026 | 10mg | Freedom Diagnostics | 99.51% | Confirmed (LC-MS/MS) | COA PDF |
| WQ988T | 11 Mar 2026 | 10mg | Freedom Diagnostics | 99.67% | Confirmed (LC-MS/MS) | COA PDF |
| BPC11182025-J | 21 Nov 2025 | 10mg | Freedom Diagnostics | 99.25% | Confirmed (LC-MS/MS) | COA PDF |
BPC-157 sizes and pricing
| Size | Price | Per mg |
|---|---|---|
| 10mg | $40 | $4.00 per mg |
| 20mg | $80 | $4.00 per mg |
Published literature on BPC-157
The mechanisms above trace to peer-reviewed studies indexed on PubMed. These are independent third-party publications, not Aspect Peptides claims. Browse indexed research on PubMed.
BPC-157 frequently asked questions
Is BPC-157 approved for human use?
No. BPC-157 is not approved by the FDA or any regulatory agency for human use and is not a drug, supplement, or medicine. The FDA has flagged it in compounded and supplement products. It is offered here strictly as a reference material for in-vitro laboratory research.
What does the research on BPC-157 show?
Published work is almost entirely preclinical (animal and cell studies). It has been characterized for VEGF and VEGFR2 pathway activity, nitric-oxide synthase system interaction, growth-hormone-receptor expression in cultured fibroblasts, and collagen-gene expression markers. No human clinical efficacy has been established.
How is BPC-157 handled in research?
It ships as a lyophilized powder and is reconstituted in the laboratory per the researcher's own protocol. Reconstitution volume, diluent and study design are determined by the qualified researcher; we supply the compound and its analytical data only.
Documented to 99.51% purity by HPLC · third-party COA every lot · from $40 · For laboratory research use only.
Related Regenerative & Repair compounds
- TB-500 - Thymosin β-4 fragment studied for actin regulation and tissue repair.
- BPC-157 / TB-500 - Co-formulated repair-research blend in a single vial.
- BPC-157 / TB-500 / KPV - BPC-157, TB-500 and KPV co-formulated in a single vial.
- GHK-Cu - Copper tripeptide studied in skin-remodeling research.
- KPV - α-MSH C-terminal fragment studied for inflammatory signaling.
- ARA-290 - Erythropoietin-derived peptide studied for neural repair.